DataSheet_1_Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma.docx
Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three decades. T-cell-based immunotherapies such as immune-checkpoint inhibitors and chimeric antigen receptor T-cell therapy have prolonged the survival of patients with other cancers and have undergone early-phase clinical evaluation in glioblastoma patients. However, a major challenge for T-cell-based immunotherapy of glioblastoma and other solid cancers is T-cell infiltration into tumours. This process is mediated by chemokine-chemokine receptor and integrin-adhesion molecule interactions, yet the specific nature of the molecules that may facilitate T-cell homing into glioblastoma are unknown. Here, we have characterised chemokine receptor and integrin expression profiles of endogenous glioblastoma-infiltrating T cells, and the chemokine expression profile of glioblastoma-associated cells, by single-cell RNA-sequencing. Subsequently, chemokine receptors and integrins were validated at the protein level to reveal enrichment of receptors CCR2, CCR5, CXCR3, CXCR4, CXCR6, CD49a, and CD49d in glioblastoma-infiltrating T-cell populations relative to T cells in matched patient peripheral blood. Complementary chemokine ligand expression was then validated in glioblastoma biopsies and glioblastoma-derived primary cell cultures. Together, enriched expression of homing receptor-ligand pairs identified in this study implicate a potential role in mediating T-cell infiltration into glioblastoma. Importantly, our data characterising the migratory receptors on endogenous tumour-infiltrating T cells could be exploited to enhance the tumour-homing properties of future T-cell immunotherapies for glioblastoma.
History
References
- https://doi.org//10.1002/cti2.1050
- https://doi.org//10.1038/s41598-020-68011-4
- https://doi.org//10.1056/NEJMoa1103849
- https://doi.org//10.1016/S1470-2045%2818%2930139-6
- https://doi.org//10.3390/ijms21082759
- https://doi.org//10.1056/NEJMoa1610497
- https://doi.org//10.1093/neuonc/noaa277
- https://doi.org//10.1016/j.it.2012.07.004
- https://doi.org//10.1158/1078-0432.CCR-17-2617
- https://doi.org//10.1158/0008-5472.CAN-14-2458
- https://doi.org//10.1093/neuonc/noy084
- https://doi.org//10.1016/j.cell.2021.01.022
- https://doi.org//10.1016/j.cell.2020.04.055
- https://doi.org//10.1371/journal.ppat.1007633
- https://doi.org//10.1002/eji.201343751
- https://doi.org//10.1111/imr.12650
- https://doi.org//10.1038/s41467-018-07053-9
- https://doi.org//10.1136/jitc-2021-003329
- https://doi.org//10.3389/fimmu.2020.00835
- https://doi.org//10.1158/1078-0432.CCR-17-1846
- https://doi.org//10.1002/cti2.1191
- https://doi.org//10.1016/j.cell.2019.06.024
- https://doi.org//10.1016/j.stem.2009.03.014
- https://doi.org//10.1002/cyto.a.22257
- https://doi.org//10.1155/2016/8941260
- https://doi.org//10.1038/jid.2009.313
- https://doi.org//10.1038/ni.1716
- https://doi.org//10.1016/j.jaut.2011.11.006
- https://doi.org//10.1074/jbc.M212077200
- https://doi.org//10.1093/glycob/cwv100
- https://doi.org//10.1038/385640a0
- https://doi.org//10.1038/79738
- https://doi.org//10.1021/cb700159m
- https://doi.org//10.3390/ijms19020485
- https://doi.org//10.1038/s41568-019-0205-x
- https://doi.org//10.4049/jimmunol.181.5.3099
- https://doi.org//10.1016/j.cell.2021.07.015
- https://doi.org//10.1136/jitc-2021-003100
- https://doi.org//10.1038/s41551-021-00737-6
- https://doi.org//10.1016/j.ajpath.2011.11.032
- https://doi.org//10.1046/j.1365-2249.2002.01947.x
- https://doi.org//10.3389/fimmu.2019.02395
- https://doi.org//10.3389/fimmu.2018.01214
- https://doi.org//10.4049/jimmunol.177.11.8053
- https://doi.org//10.1074/jbc.274.43.31076
- https://doi.org//10.1371/journal.pone.0033005
- https://doi.org//10.1007/s11060-019-03172-5
- https://doi.org//10.1007/s00262-007-0336-x
- https://doi.org//10.1007/s11060-013-1236-x
- https://doi.org//10.1038/ncomms9644
- https://doi.org//10.1523/JNEUROSCI.0123-04.2004
- https://doi.org//10.1128/JVI.79.17.11457-11466.2005
- https://doi.org//10.1093/carcin/bgq224
- https://doi.org//10.1016/j.immuni.2019.04.010
- https://doi.org//10.3892/ijo.21.4.707
- https://doi.org//10.1016/S0014-5793%2898%2901384-2
- https://doi.org//10.1016/j.jneuroim.2008.04.016
- https://doi.org//10.1158/1078-0432.CCR-10-2557
- https://doi.org//10.1158/0008-5472.CAN-06-3280
- https://doi.org//10.1126/scitranslmed.3004888
- https://doi.org//10.1158/2326-6066.CIR-20-0427
- https://doi.org//10.1189/jlb.2VMA0915-432RR
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity